ExpreS2ion Biotech Holding (EXPRS2) Fair Value & Analysis
Healthcare · SE · Market cap 14.2M SEK
Fair value as of: Jul 12, 2026
From 1 valuation models · updated today
Fair value updated Jul 12, 2026 — revised from kr 16.25 to kr 2.84 (−82.5%) since Jun 24, 2026. Share price −9.1% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 1.42 – kr 28.05 · fair‑value band kr 1.88 – kr 3.55 · the kr 1.44 price screens below the kr 2.84 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
ExpreS2ion Biotech Holding (EXPRS2) currently trades at kr 1.44, while our model-based Fair Value estimate is kr 2.84 — implying the stock looks roughly 97.2% undervalued today. We read business quality at 22/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at 10.9M SEK. Revenue grew 132.3% year over year. It earns a return on equity of -88.0%. The balance sheet holds a net cash position of 45.3M SEK. Fundamentals as of Jul 12, 2026
Our scenario range runs from kr 1.88 (bear case) to kr 3.55 (bull case); at kr 1.44, the current price sits below that range. For context, the median of 10 Healthcare peers we cover trades at -32% fair-value upside — at 97%, EXPRS2 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalovirus vaccine program to treat infectious diseases, as well as vaccines for Nipah virus, Malaria, and influenza. In addition, the company offers a human clinical Phase III-validated technology platform for the development and production of the active material in vaccines under the GlycoX-S2. Further, it out licenses its ExpreS2 platform to research institutes and pharmaceutical companies; and sells ExpreS2 test kits and reagents for research purposes or diagnostic applications. The company has collaboration agreement with University of Oxford for the development of vaccine for malaria. …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ExpreS2ion Biotech Holding reported revenue of kr 3.7M in FY2025 versus kr 12.2M in FY2021, a compound −26.1%/yr. Reported net income was −kr 38.1M in FY2025.
Is EXPRS2 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.30 | R$9.67 | -82% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ExpreS2ion Biotech Holding (EXPRS2) undervalued?
What is the fair value of EXPRS2?
What is the quality score of EXPRS2?
What is the revenue of ExpreS2ion Biotech Holding (EXPRS2)?
What is the net profit margin of EXPRS2?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full ExpreS2ion Biotech Holding analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.